Bank of New York Mellon Corp Takes $342,000 Position in MediWound Ltd. (NASDAQ:MDWD)

Bank of New York Mellon Corp purchased a new stake in shares of MediWound Ltd. (NASDAQ:MDWD) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 22,010 shares of the biopharmaceutical company’s stock, valued at approximately $342,000. Bank of New York Mellon Corp owned approximately 0.24% of MediWound at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of MDWD. Rosalind Advisors Inc. lifted its position in shares of MediWound by 5.7% during the second quarter. Rosalind Advisors Inc. now owns 513,490 shares of the biopharmaceutical company’s stock worth $7,969,000 after acquiring an additional 27,500 shares in the last quarter. Essex Investment Management Co. LLC raised its stake in shares of MediWound by 241.6% during the 1st quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock valued at $1,888,000 after purchasing an additional 93,705 shares during the period. Silverberg Bernstein Capital Management LLC lifted its holdings in MediWound by 7.8% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock worth $1,214,000 after purchasing an additional 6,200 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in MediWound in the 1st quarter worth about $427,000. 46.83% of the stock is owned by institutional investors.

MediWound Stock Down 1.7 %

Shares of NASDAQ MDWD opened at $16.99 on Thursday. The firm has a market capitalization of $157.74 million, a P/E ratio of -12.31 and a beta of 0.83. The stock’s 50-day simple moving average is $18.15 and its two-hundred day simple moving average is $17.16. MediWound Ltd. has a twelve month low of $7.45 and a twelve month high of $24.00.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.26). MediWound had a negative return on equity of 52.49% and a negative net margin of 99.17%. The company had revenue of $5.06 million during the quarter, compared to the consensus estimate of $5.07 million. As a group, research analysts anticipate that MediWound Ltd. will post -2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on MDWD. StockNews.com raised shares of MediWound to a “sell” rating in a report on Monday, August 5th. Maxim Group increased their target price on shares of MediWound from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $28.00 price target on shares of MediWound in a report on Thursday, August 15th.

MediWound Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.